iBio(IBIO) will be developing COVID-19 vaccine candidates
iBio, inc., is a leader in plant-based biologics manufacturing using their FastPharming facilities that combine vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks, and other proteins. iBio is seeing some upside already today as the stock is trading 40% higher during pre-market hours.
iBio is part of the “Blue Angel” initiative, they established facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic. On March 11, 2020, iBio filed four provisional patent applications with the U.S. Patent and Trademark Office in support of the VLP platform, as well as other technologies for treating or preventing infections with the SARS-CoV-2 virus. This is huge since it hints we are getting closer to the vaccine people need, and the vaccine iBio will produce. We have seen these pharmaceutical stocks rise in such large numbers, some even 400% in one day, and I don’t think we will stop seeing them as the coronavirus shows no signs of getting better. The world not only needs a vaccine, but they also need one quick, and who sits in a better position then iBio themselves.